Sanofi Stops Lung Disease Drug Study
Sanofi paused a study for a lung disease drug, saying it was for business reasons.
Sanofi stopped a key drug study. This study tested a new medicine for a serious lung problem. The company called off the study for "strategic business reasons."
The drug is called SAR445399. It is a monoclonal antibody. The study was in its second phase. This phase checks if a drug works and is safe for patients. The drug aimed to help people with non-cystic fibrosis bronchiectasis.
This lung disease causes airways to get wide and scarred. It makes breathing hard. Patients often get bad infections. Finding new ways to treat it is important.
Sanofi did not share more details. The company often reviews its drug pipeline. It decides which programs to continue. This decision could mean the drug was not working as expected. It might also mean Sanofi changed its focus.
For patients, this news means a potential new treatment is on hold. Researchers will keep working to find other ways to fight this tough lung disease.
Source: FierceBiotech
More from Biotech
